https://www.civilizationventures.com/

[https://assets-global.website-files.com/641d7b661f0152a85c086c76/64e3a8c6c86b64529cf6a312_Civilization Ventures_Montage3_V2 (1)-transcode.mp4](https://assets-global.website-files.com/641d7b661f0152a85c086c76/64e3a8c6c86b64529cf6a312_Civilization Ventures_Montage3_V2 (1)-transcode.mp4)

60+ Investments, 9 Exits, 4 Unicorns in 7 Years

2017

CV Fund I

Civilization launches with a $1M pilot fund to back innovators in genomics + diagnostics, digital health and synthetic biology (including gene + cell therapies).

2018

Rocket Pharma listed (NASDAQ: RCKT)

Rocket Pharma lists on Nasdaq, and a unicorn is born. Rocket has multiple first-in-class gene therapies in clinical trials to cure devastating inherited diseases.

2019

Singular Bio acquired by Invitae

Singular Bio is acquired by Invitae to help increase access to accurate genetic screening in early pregnancy.